Qiagen Forms Molecular Dx Joint Venture in Singapore

Dec 03, 2007

NEW YORK (GenomeWeb News) – Qiagen is starting a joint venture in Singapore with Bio*One Capital, a biomedical investment management company based in that country, that will develop molecular diagnostic assays for genetic and infectious diseases, the firms said today.

The venture, called Dx Assays, should be operational by early 2008 and will be staffed with over 30 researchers, the companies said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

Main menu